Changzhou Maternal and Child Care Hospital
5
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells
Role: collaborator
To Improve the Rate of Mother's Own Milk Feeding of Premature Infants in NICU
Role: collaborator
Screening and Follow-up Study of Neonatal Jaundice Based on Mobile Network
Role: collaborator
Improving Mother Milk Feeding Benefits in Neonatal Intensive Care Units
Role: collaborator
Study on Clinical Prognosis, Risk Factors and Genetic Basis of Congenital Heart Disease
Role: collaborator
All 5 trials loaded